HIV evolution: CTL escape mutation and reversion after transmission
By A. Leslie, K. Pfafferott, P. Chetty, R. Draenert, M. Addo, M. Feeney, Yanhua Tang, Edward C. Holmes, Todd M. Allen, J. Prado and 19 more. Nature Medicine, 2004
937 citations recorded by the source corpus.
Subfields: Immunology, Infectious Diseases, Virology
View Paper: https://www.semanticscholar.org/paper/28f4c5e0f2f108d1acfee152b8d856226529cdc7
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- D. Bowen
- C. Moore
- David M. McCandlish
- C. Walker
- Peter Simmonds
- Danni Ramduth
- I. James
- K. Pfafferott
Citations in the corpus
- Adaptive immune responses in acute and chronic hepatitis C virus infection (2005, background): “Following transmission of HIV or SIV to hosts expressing non-selecting MHC, certain epitopes with potentially high associated fitness cost revert to wild-type sequenc”
- Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA (2004, methodology): “Viral sequencing Sequencing of HIV proviral DNA from patients in the Durban cohort was undertaken as previously describe”
- Epistasis and the Dynamics of Reversion in Molecular Evolution (2016, background): “However, we may expect reversion rates to sometimes increase in time under conditions where fitness is non-transitive (e.g. Kerr et al. 2002) or when environments change in a cyclic manner (e.g. Leslie et al. 2004; Hensley et al. 2009; Bergland et al. 2014).”
- Genetic diversity and evolution of hepatitis C virus--15 years on. (2004, background): “In the latter case, it has been demonstrated that the immune selection mediated by B8 and B5801 occurred only with likely significant fitness cost to the virus; it invariably reverted to the original, ‘wild-type’ sequence on transmission to other individuals with different human leukocyte antigen (H”
- Translating HIV sequences into quantitative fitness landscapes predicts viral vulnerabilities for rational immunogen design (2013, neutral): “…et al., 2005; Brockman et al., 2010; Brockman et al., 2007; Brumme et al., 2009; Dahirel et al., 2011; Draenert et al., 2004; Ferrari et al., 2011; Leslie et al., 2004; Letourneau et al., 2007; Martinez-Picado et al., 2006; Miura et al., 2009; Miura et al., 2009; Schneidewind et al., 2008;…”